A shorter isoform of AR primarily expressed in castration-resistant prostate cancer (CRPC), ARv7, indicates poorer prognosis in prostate cancer (PCa), as it lacks the LBD and remains overly active even in absence of the hormone, the mechanism of which is still not fully understood (8). This evidence concerns the gene AR and prostate cancer.